

FITC anti-human CD8a

Catalog # / Size: 2105025 / 25 tests
2105030 / 100 tests

2105250 / 500 tests

2105300 / 100 µg

Clone: RPA-T8

Isotype: Mouse IgG1, κ


Reactivity: Human

Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.

Formulation: microg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Workshop Number: IV T171

Concentration: microg sizes: 0.5 mg/ml
test sizes: lot-specific



Human peripheral blood lymphocytes stained with RPA-T8 FITC

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the microg size, the suggested use of this reagent is ≤ 1.0 microg per million cells in 100 µL volume. **Test size products are transitioning from 20 µL to 5 µL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 µL staining volume or per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections³ and costimulation of T cell responses⁴. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 301018).

Application References:

- Knapp W, *et al.* Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
- Schlossman S, *et al.* Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Mack CL, *et al.* 2004. *Pediatr. Res.* 56:79. (IHC)
- Magidovich E, *et al.* 2007. *P. Natl. Acad. Sci. USA* 104:13022.
- Thakarl D, *et al.* 2008. *J. immunol.* 180:7431. [PubMed](#)
- Kmieciak M, *et al.* 2009. *J. Transl. Med.* 7:89. (FC) [PubMed](#)
- Thakral D, *et al.* 2008. *J. Immunol.* 180:7431. (FC) [PubMed](#)

7. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
 8. Rout N, *et al.* 2010. *PLoS One* 5:e9787. (FC)
-

Description: CD8a is a 32-34 kD type I glycoprotein. It forms a homodimer (CD8a/a) or heterodimer (CD8a/b) with CD8b. CD8, also known as T8 and Leu2, is a member of the immunoglobulin superfamily found on the majority of thymocytes, a subset of peripheral blood T cells, and NK cells (which express almost exclusively CD8a homodimers). CD8 acts as a co-receptor with MHC class I-restricted T cell receptors in antigen recognition and T cell activation, and has been shown to play a role in thymic differentiation. Two domains in CD8a are important for function: the extracellular IgSF domain binds the α_3 domain of MHC class I and the cytoplasmic CXCP motif binds the tyrosine kinase p56 Lck.

Antigen
References: 1. Barclay N, *et al.* 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.